Status:

TERMINATED

Rituximab to Prevent Recurrence of Proteinuria

Lead Sponsor:

George W. Burke

Collaborating Sponsors:

Genentech, Inc.

National Institutes of Health (NIH)

Conditions:

FSGS

Proteinuria

Eligibility:

All Genders

7-65 years

Phase:

PHASE3

Brief Summary

The investigators propose to study novel targets of rituximab in podocytes, with a particular focus on recurrent focal segmental glomerulosclerosis (FSGS). The proposed study has strong clinical impli...

Detailed Description

A total of 60 patients will be enrolled in the study.

Eligibility Criteria

Inclusion

  • Inclusion:
  • Patient has been fully informed and has signed a dated IRB-approval informed consent form.
  • Age 7-65 years.
  • Male and Females diagnosed of FSGS by kidney biopsy. Kidney biopsy report is not required once the physician confirms the diagnosis. Transcribed reports from referring physicians are also valid.
  • Exclusion:
  • Recipient or donor is seropositive for human immunodeficiency virus (HIV), Hepatitis C viruses, or Hepatitis B virus antigenemia.
  • Patient has a current malignancy or a history of malignancy (within the past 5 years), except non-metastatic basal or squamous cell carcinoma of the skin that has been treated successfully or carcinoma in situ of the cervix that has been treated successfully.
  • Patient has uncontrolled concomitant infections and/or severe diarrhea, vomiting, active upper gastro-intestinal tract malabsorption or an active peptic ulcer or any other unstable medical condition that could interfere with study objectives.
  • Patient is pregnant or lactating.
  • Patient has any form of substance abuse, psychiatric disorder or a condition that, in opinion of the investigator, may invalidate communication with the investigator.
  • Patients with a defined genetic cause of FSGS.

Exclusion

    Key Trial Info

    Start Date :

    February 1 2012

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    October 1 2016

    Estimated Enrollment :

    30 Patients enrolled

    Trial Details

    Trial ID

    NCT01164098

    Start Date

    February 1 2012

    End Date

    October 1 2016

    Last Update

    September 20 2018

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    University of Miami

    Miami, Florida, United States, 33136